ArticleTH open : companion journal to thrombosis and haemostasis2026
Cost Avoidance Associated with Aspirin De-Prescribing Among Patients Receiving Warfarin.
Article in TH open : companion journal to thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: From 2017 to 2018, the Michigan Anticoagulation Quality Improvement Initiative (MAQI Objective: To determine the amount reimbursed from insurance for bleeding and thrombotic events; to estimate the reimbursement savings from our antithrombotic stewardship intervention in US dollars. Methods: Insurance claims data were linked to the MAQI Results: Major bleeding events were associated with a median inpatient/emergency department (ED) cost of $13,661 (IQR: $6,601). Nonmajor bleeding events had a median inpatient cost of $11,678 (IQR: $6,050) and a median ED cost of $457 (IQR: $517). Major bleeding events were reduced by 1.3 bleeds per 100-patient-years postintervention for a savings of $17,759 per 100-patient-years. Nonmajor bleeding was reduced by 8.5 bleeds per 100-patient-years postintervention, for a savings of $26,535 per 100-patient-years. Thrombosis rates were similar pre- and postintervention. Overall estimated savings are $44,294 per 100-patient years or $443 per patient annually. Conclusion: Our antithrombotic stewardship intervention was associated with healthcare system payment savings and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.